Quoin Pharmaceuticals Ltd. (QNRX) Overview
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $4.88
- Previous close
- $5.26
- Change
- -$0.38
- Change (%)
- -7.22%
- Close date
- 2026-09-29
- Previous close date
- 2026-09-28
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- QNRX
- -66.15%
- S&P 500
- (m)
1 year
- QNRX
- -30.61%
- S&P 500
- (m)
3 years
- QNRX
- -96.64%
- S&P 500
- (m)
5 years
- QNRX
- -99.99%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
(m)
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|
31 Dec 2021 ○ Estimate (m) ● Actual -0.01
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2021 | 31 Dec 2021 | (m) | -0.01 | (m) | (m) |
| 1 Jan 2020 | 31 Dec 2020 | (m) | -0.70 | (m) | (m) |
| 1 Jan 2019 | 31 Dec 2019 | (m) | -0.52 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
No complete retained periods.
31 Dec 2021 ■ Revenue 0.00M ■ Earnings -21.46M — Profit margin (m)
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $4.88 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning QNRX
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending (m).
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- (m)
- Profit margin
- (m)
- Return on assets · 12 month
- (m)
- Stock compensation expense · all employees · 12 months
- (m)
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- (m)
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 98.23K
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -30.39%*
- Total return · month
- -20.26%*
- Total return · quarter
- 7.36%*
- Total return · half year
- -23.80%*
- Total return · year to date
- -66.15%*
- Total return · 1 year
- -30.61%*
- Total return · 3 years
- -96.64%*
- Total return · 5 years
- -99.99%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- (m)
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
Quoin Pharmaceuticals Ltd. Overview
View more →(m)
(m)
- SEC CIK
- 1671502
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 42127 PLEASANT FOREST COURT, ASHBURN, Virginia, 20148-7349, United States
- Fiscal year end
- (m)
- Phone
- 703 980 4182
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |